The AlphaLISA® immunoassay kit for human Bruton's tyrosine kinase (BTK) enables the quantitative determination of human BTK in buffer and cell lysates using a homogeneous AlphaLISA assay (no wash steps).
For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
BTK is a cytoplasmic tyrosine kinase present in B-cells. It is associated with the B-cell receptor and receptors of the toll family. Upon activation, BTK will activate the Nf-kB pathway. This will induce maturation of B-cells into antibody producing cells and also increase the secretion of activating cytokines (such as IL-2). The protein is absent or non-functional in diseases such as aglobularia, and is involved via hyperactivation in inflammation and auto-immune diseases. Also, several leukemia-like cancers have dysregulation of BTK.
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Unit Size||5,000 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.